- Home
- OBIO vs LNZA Comparison
OBIO vs LNZA Comparison
Compare OBIO & LNZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | LNZA |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | 192 |
| Industry | Medicinal Chemicals and Botanical Products | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 231.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | OBIO | LNZA |
|---|---|---|
| Price | $4.01 | $25.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $14.25 | $14.00 |
| AVG Volume (30 Days) | ★ 147.2K | 42.3K |
| Earning Date | 05-11-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,482,000.00 | N/A |
| Revenue This Year | N/A | $55.80 |
| Revenue Next Year | $12.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1169.22 | N/A |
| 52 Week Low | $2.20 | $0.19 |
| 52 Week High | $5.42 | $44.00 |
Technical Indicators
Market Signals| Indicator | OBIO | LNZA |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 47.21 |
| Support Level | $4.02 | $22.08 |
| Resistance Level | $4.17 | $29.51 |
| Average True Range (ATR) | 0.22 | 3.73 |
| MACD | -0.03 | -0.99 |
| Stochastic Oscillator | 26.98 | 5.16 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a provider of carbon management and conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical industrial inputs. Its mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging scalable biotechnology solutions to maximize the value of domestic resources. The company operates in North America, Europe, the Middle East, Africa (EMEA), Asia, and Australia, with the majority of its revenue generated from North America.